Trial Profile
A study of AMO-1 for the treatment of fragile X syndrome
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2017
Price :
$35
*
At a glance
- Drugs Diazepinomicin (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- 21 Dec 2016 According to BELLUS Health media release, the company expects to initiate this trial in the first half of 2017.
- 07 Jun 2016 According to an AMO Pharma media release, the company plans to initiate this study in 2016.
- 02 Oct 2015 New trial record